Brain Tumor, Pediatric Clinical Trial
Official title:
Social Emotional Development in Young Children With Cancer
Verified date | May 2024 |
Source | St. Jude Children's Research Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Many children with cancer are diagnosed in early childhood, and as such, will likely miss key social experiences such as participation in preschool or kindergarten, playing on playgrounds, and other normative experiences. In typically-developing children, it is known that these experiences - and the skills that are learned during them - are critical to later well-being. Very little is known about the psychological functioning of young children with cancer, as studies have predominantly focused on those who are older (at least 8 years of age). This study will explicitly assess social functioning in preschool-aged children with cancer and follow the development of their social functioning from the end of treatment into survivorship. The goals of this pilot study are to begin to assess the impact of missed early childhood social experiences, as well as the interaction with developing neurocognitive problems. PRIMARY OBJECTIVE: Explore the impact of cancer in the central nervous system on social functioning of young children (ages 4-6) after completion of therapy.
Status | Active, not recruiting |
Enrollment | 64 |
Est. completion date | September 2024 |
Est. primary completion date | September 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 4 Years to 6 Years |
Eligibility | Inclusion Criteria: - Primary Diagnosis of a brain or non-CNS solid tumor - Between 4 and 6 years of age at enrollment - Between 6 and 12 months post-therapy at the time of enrollment - Treatment plan included chemotherapy - English speaking - Cognitive and language capacity to complete measures Exclusion Criteria: - Diagnosis of a genetic disorder/pre-existing neurodevelopmental condition associated with neurocognitive or social impairment (e.g., autism, Neurofibromatosis Type 1 (NF1), Down syndrome) - Solid tumor patients who required CNS-directed therapy (e.g., radiation, intrathecal chemotherapy) - Inability or unwillingness of research participant or legal guardian/representative to give written informed consent. |
Country | Name | City | State |
---|---|---|---|
United States | St. Jude Children's Research Hospital | Memphis | Tennessee |
Lead Sponsor | Collaborator |
---|---|
St. Jude Children's Research Hospital | American Cancer Society, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Social functioning as assessed by parent-completed measures and child-completed measures | Descriptive statistics will be provided. Parents will complete the Social Competence Inventory, Quality of Play Questionnaire, and the NIH Toolbox. Patients completed measures include the subtests from the NIH Toolbox, Challenging Situations Task, and Developmental Neuropsychological Assessment (2nd edition). Analyses will be completed to assess performance on these measures at each time point and to assess change over time. Analyses will be completed by diagnostic group (brain tumor versus solid tumor). | All measures will be completed at both the study enrollment and 24±3 months later |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03936465 -
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer
|
Phase 1 | |
Recruiting |
NCT04738162 -
Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Supratentorial Brain Tumors
|
Phase 2 | |
Not yet recruiting |
NCT06093165 -
RE-irradiation of Diffuse MIdline Glioma paTients
|
N/A | |
Recruiting |
NCT05298995 -
GD2-CAR T Cells for Pediatric Brain Tumours
|
Phase 1 | |
Recruiting |
NCT05709522 -
Neurocognitive and Psychosocial Outcomes Among Pediatric Brain Tumor and Blood Cancer Patients
|
||
Recruiting |
NCT04722237 -
Acceptance and Commitment Therapy for Neuro-Oncology Wellbeing
|
N/A | |
Recruiting |
NCT06309251 -
Effectiveness and Impact on the Quality of Life of Ketogenic Diet in Pediatric Patients
|
||
Recruiting |
NCT04670016 -
HRQL and Symptom Assessment for Patients With DIPG or Recurrent and Re-irradiated Brain Tumours and Their Caregivers
|
||
Active, not recruiting |
NCT03361033 -
Components of Social Functioning in Survivors of Pediatric Brain Tumors
|
||
Active, not recruiting |
NCT04525014 -
RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors
|
Phase 1 | |
Recruiting |
NCT05672043 -
Genetic and Molecular Risk Profiles of Pediatric Malignant Brain Tumors in China
|
||
Recruiting |
NCT05553899 -
Utility of PET-MRI in Surveillance of Paediatric Brain Tumours
|
N/A | |
Completed |
NCT03871686 -
Promotion of Well-being of Young Adult Brain Cancer Survivors
|
N/A | |
Withdrawn |
NCT04019470 -
Immunomodulation Analysis of Radiation Therapy in Pediatric Malignant Brain Tumors
|
||
Active, not recruiting |
NCT04023669 -
Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
|
Phase 1 | |
Suspended |
NCT05169944 -
Magrolimab in Children and Adults With Recurrent or Progressive Malignant Brain Tumors
|
Phase 1 |